Second Circuit Revives Claims in Oral Phenylephrine Labeling Lawsuit

• A consolidated class action lawsuit against oral phenylephrine decongestant manufacturers has seen some claims revived after the Second Circuit's decision.
• The plaintiffs claimed that products containing oral phenylephrine were not effective in decongesting, despite FDA requirements for labeling them as such.
• The Second Circuit revived claims regarding false advertising and labeling, particularly with regards to 'maximum strength' designations on product labels.
• The appeals court also vacated the dismissal of claims related to brand-name products approved through the FDA's new drug application process.

Indeed, defendant manufacturers followed the FDA's prescribed labeling requirements by designating their decongestants' purpose as decongestion. Defendant manufacturers cannot now be sued for complying with those FDA specifications.

A consolidated class action lawsuit against manufacturers and distributors of oral phenylephrine decongestant medications has seen some claims revived after the Second Circuit largely affirmed a lower court's dismissal. The plaintiffs, who sued companies like Johnson & Johnson, Procter & Gamble, Pfizer, Bayer Healthcare, CVS Pharmacy, Walgreens, Target, and Amazon, claimed that products containing oral phenylephrine were not effective in decongesting. However, the FDA requires manufacturers to label these medications as effective, which has led judges to rule that companies cannot be held liable for complying with FDA specifications.

The Second Circuit's decision mostly agreed with the lower court's finding that federal law preempts state law claims and that plaintiffs lacked statutory standing to bring their RICO claim. However, the appeals court revived claims regarding false advertising, specifically the use of 'maximum strength' designations on product labels. Additionally, the panel vacated the dismissal of claims related to brand-name products approved through the FDA's new drug application process.

The lawsuit is part of a larger trend of consumer class actions against pharmaceutical companies. In this case, plaintiffs claimed that manufacturers and distributors of oral phenylephrine decongestant medications were aware of the ingredient's ineffectiveness but continued to sell it as 'maximum strength.' The FDA requires manufacturers to follow specific labeling requirements, which has led judges to rule that companies cannot be held liable for complying with these regulations. However, the Second Circuit's decision also highlighted the complexity of federal law and its relationship to state law claims.

The appeals court's decision was penned by Senior U.S. Circuit Judge Denny Chin, who explained in a footnote that the finding regarding statutory standing was actually a question of whether plaintiffs had a cause of action under the statute. This nuance highlights the need for careful analysis of federal law and its implications for consumer class actions.

The Second Circuit's decision has significant implications for lawyers representing consumers in oral phenylephrine decongestant lawsuits. The revived claims regarding false advertising and labeling, particularly with regards to 'maximum strength' designations, provide a new avenue of attack for plaintiffs. This development is crucial as it allows consumers to hold manufacturers accountable for their marketing practices.

The decision also underscores the importance of understanding federal law and its relationship to state law claims. As consumer class actions continue to be filed against pharmaceutical companies, this ruling serves as a reminder that careful analysis of federal regulations is essential in determining the viability of claims.

Lawyers representing consumers in oral phenylephrine decongestant lawsuits should watch for the possibility of revived claims regarding false advertising and labeling, particularly with regards to 'maximum strength' designations.

Source: Original reporting via Courthouse News